[66] demonstrated that neither genetic deletion of CCL5 nor pharmacological blockade using a CCL5 inhibitor (met-RANTES) altered BP in an Ang II-induced hypertension model (490 ng/kg/min), although both approaches improved vascular function, reduced vascular reactive oxygen species, and decreased T-cell infiltration into PVAT. The gene discussed is CCL5; the disease is hypertensive disorder.